Immuneel Therapeutics, a Bengaluru-based biotech startup, raised ₹100 crore in a Series B funding round led by Singularity AMC and Rainmatter by Zerodha, with participation from founder Kiran Mazumdar-Shaw, Eight Roads Ventures, F-Prime Capital, and other investors, the company announced. The funds will support scaling manufacturing capacity and advancing its gene and cell therapy pipeline, including the commercialisation of Qartemi, a CAR-T therapy for Non-Hodgkin Lymphoma.
Founded in 2018 by Kiran Mazumdar-Shaw, Kush M Parmar, and Siddhartha Mukherjee, Immuneel Therapeutics develops affordable cell and gene therapies to fight cancer. CEO Amit Mookim said the capital will be used to expand GMP manufacturing capabilities and enhance localisation and manufacturing expertise to support current and future programs. The company aims to increase its presence across the Asia Pacific and Middle East regions.
Immuneel’s focus on CAR-T cell therapy addresses a critical need for advanced cancer treatments in India and beyond. Qartemi, its approved therapy for Non-Hodgkin Lymphoma, targets a blood cancer affecting the lymphatic system. The funding round reflects growing investor interest in biotech startups working on innovative therapies, with backers including prominent venture capital firms and high-net-worth individuals.
A substantial portion of the ₹100 crore will be allocated to commercialising Qartemi and expanding Immuneel’s manufacturing infrastructure. The company’s efforts align with broader trends in biotech investment and the push to improve access to advanced cancer therapies in emerging markets, according to inc42.com.